Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sutro Biopharma is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 259 staff and has a trailing 12-month revenue of around $69.8 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $6.87 |
|---|---|
| 52-week range | $3.33 - $10.15 |
| 50-day moving average | $7.52 |
| 200-day moving average | $6.21 |
| Wall St. target price | $22.13 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.47 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.87 from 2023-02-06
| 1 week (2023-01-31) | -5.11% |
|---|---|
| 1 month (2023-01-06) | -16.32% |
| 3 months (2022-11-07) | -8.76% |
| 6 months (2022-08-05) | 19.27% |
| 1 year (2022-02-03) | -28.88% |
|---|---|
| 2 years (2021-02-05) | -73.94% |
| 3 years (2020-02-07) | 11.75 |
| 5 years (2018-02-03) | N/A |
| Revenue TTM | $69.8 million |
|---|---|
| Gross profit TTM | $-42,520,000 |
| Return on assets TTM | -18.56% |
| Return on equity TTM | -47.82% |
| Profit margin | -175.85% |
| Book value | $4.21 |
| Market capitalisation | $421.3 million |
TTM: trailing 12 months
We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $3.33 up to $10.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.9323. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.